PALI-2108 for Ulcerative Colitis

PALI-2108 for Ulcerative Colitis
71%60%49%Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12Apr 26 • YES 66.4%Apr 27 • YES 61.0%Apr 28 • YES 58.8%Apr 29 • YES 56.0%Apr 30 • YES 54.3%May 1 • YES 53.6%May 2 • YES 53.6%May 3 • YES 53.6%May 4 • YES 53.6%May 5 • YES 53.6%May 7 • YES 54.8%May 8 • YES 56.5%May 11 • YES 56.8%May 12 • YES 56.8%
Palisade Bio ($PALI)
No stock closeNo stock close$2.18$1.96$1.75Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12Apr 27 • PALI $1.96Apr 28 • PALI $1.95Apr 29 • PALI $1.93Apr 30 • PALI $2.00May 1 • PALI $1.99May 4 • PALI $2.13May 5 • PALI $1.97May 6 • PALI $2.00May 7 • PALI $1.99May 8 • PALI $1.80May 11 • PALI $1.94May 12 • PALI $1.92

Will this trial show a positive result on incidence of Treatment-Emergent Adverse Events (TEAE) or abnormal clinical laboratory measure, electrocardiogram (ECG), or vital sign. [ Safety and Tolerability ]?

Paper Trading
Create account to trade
ClinicalTrialModel PositionsModel ReasoningOracle
Primary Completion
7/7/25
Study Completion
8/7/25
Sponsor
Palisade Bio
Ticker
$PALI
Type
Phase 1
Trial Status
Completed
Trial Size
89
NCT
NCT06663605
Trial Description
This completed Phase 1 study tested oral PALI-2108 in healthy adults and ulcerative colitis patients, mainly measuring side effects and abnormal lab, ECG, or vital-sign results.